Effects of a new liver support system in patients with acute-on-chronic liver failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of a Double Plasma Molecular Adsorption System (DPMAS) in patients suffering from acute-on-chronic liver failure. The DPMAS aims to remove harmful cytokines and bilirubin from the blood, potentially improving immune function and reducing mortality rates. Patients will receive standard treatment alongside DPMAS to evaluate its effectiveness in enhancing recovery. The study focuses on patients admitted to intensive care units who meet specific diagnostic criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18 or more
2. Diagnosis of Acute ontop chronic liver failure by Asian Pacific association for the study of the liver (APASL) criteria
3. Admitted to intensive care unit

Exclusion Criteria:

1. Pregnancy
2. Received steroid treatment
3. Expected dead within 24 hour
4. WBC \< 500/mm3
5. Allergy to DPMAS
6. History of organ transplant
7. Terminal illness with do not resuscitation order

Where it's running

• King Chulalongkorn Memorial Hospital
  Bangkok, Thailand Recruiting

Study contacts

• Study coordinator: Phatadon Sirivongrangson, MD
• Email: phatadon@hotmail.com
• Phone: (+66)0852447788

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Factors that affect how well mesenchymal stromal cell (MSC) therapy works for hepatitis B–related acute-on-chronic liver failure.

  This project will look back at people with hepatitis B–related ACLF who received MSC infusions to see which factors affect whether the treatment helps.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07198854

• AS1501 in ACLF: a two-stage dose study in adults with acute-on-chronic liver failure

  This Phase II study tests AS1501 given by injection in adults with early ACLF to see if it’s safe and tolerable and to guide dosing.

  Recruiting Phase 2 Shenzhen Third People's Hospital · Shenzhen, Guangdong · NCT06916585

• TAK-242 and G-CSF in ACLF: a new treatment approach for adults with acute-on-chronic liver failure

  This trial tests whether adding TAK-242, with or without G-CSF, to standard ACLF care helps patients with severe alcoholic hepatitis and ACLF.

  Recruiting Phase 2 Yaqrit Ltd · London, Greater London · NCT06890039

• Using different ROTEM cut-offs to guide blood transfusions before procedures in cirrhosis and ACLF

  This will test whether using relaxed ROTEM cut-offs to decide on blood transfusions reduces the number of transfusions without raising bleeding risk for people with cirrhosis or ACLF and severe coagulopathy who need invasive procedures.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT06831565

• Ceftazidime-avibactam vs high-dose meropenem for ACLF patients with hospital-acquired infections

  This trial tests whether ceftazidime-avibactam can better treat infections in ACLF patients than high-dose meropenem given in extended infusions, aiming to spare carbapenems if possible.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT06818565

• Evaluating a new treatment for liver failure and sepsis

  This study is testing a new treatment for people with liver failure and sepsis to see if it can help them survive and improve their organ function.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT06562803

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.